Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Table 1 Nucleoside analogues in clinical trials

Study Agents	Other agents	Disease	Dosage	Clinical trails	No Pts	Response	Reference
Clofarabine	HD Cytarabine,	Relapsed and refractory AML	22,5 mg/m² i.v qd, d1-5 GO 6 mg/m² d6	Phase II	20	CR 50%	[17]
Clofarabine		Elderly AML	20-30 mg/m² i.v qd, d1-5	Phase II	112	CR 33-56%	[18]
Clofarabine	HD Cytarabine	Relapsed and refractory AML	25 mg/m²/d 1-5d	Phase I II	38	CR 45%	[19]
Clofarabine	GO	Relapsed and refractory AML	20 mg/m²/d or 30 mg/m²/d d1-5	Phase I	14	MTD: 20 mg/m² clofarabine	[20]
Clofarabine	LD Cytarabine	Elderly untreated AML	20 mg/m² i.v qd, d1-5	Phase II	40	CR 59% CRp 6%	[21]
Sapacitabine		Elderly Relapsed and refractory AML	200 or 300 mg po bid ×7d, 400 mg po bid ×3d/w ×2w	Phase II	60	CR 10%	[22]
Elacytarabine		Relapsed and refractory AML	2,000 mg/m2 CIV d1-5q3w	Phase II	61	CR 15%	[23]

Abbreviations: GO: gemtuzumab ozogamycin; HD: high dose; LD, low dose; CRp: CR without platelet recovery; MTD: maximal tolerated dose;

ISSN: 1756-8722